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Aim of the study: To compare analgesia and adverse effects during oral morphine and 
oxycodone and transdermal fentanyl and buprenorphine administration in cancer patients 
with pain.
Patients and methods: Cancer patients treated at home and in outpatient clinics with severe 
pain (numerical rating scale score 6–10) fail to respond to non-opioids and/or weak opioids. 
All patients were randomized to either morphine, oxycodone, fentanyl or buprenorphine and 
divided into subgroups with predominant neuropathic and nociceptive pain component. Doses of 
opioids were titrated to satisfactory analgesia and acceptable adverse effects intensity. Patients 
were assessed at baseline and followed for 28 days. In all patient groups, immediate-release 
oral morphine was the rescue analgesic and lactulose 10 mL twice daily was the prophylaxis 
of constipation; no antiemetics were used as prophylaxis.
Results: A total of 62 patients participated and 53 patients completed the study. Good anal-
gesia was obtained for all 4 opioids, for both nociceptive and neuropathic pain. The use of 
co-analgesics was greater in patients with neuropathic pain. Morphine treatment was associ-
ated with less negative impact of pain on ability to walk, work and activity (trend) according 
to Brief Pain Inventory-Short Form scores and less consumption of rescue morphine. The most 
common adverse effects included nausea and drowsiness, which increased at the beginning of 
the treatment and gradually decreased over the days to come. Appetite, well-being, anxiety, 
depression, and fatigue improved. There was no constipation (the Bowel Function Index scores 
were within normal range) during the treatment with all opioids. No changes were seen for 
constipation, vomiting and dyspnea.
Conclusion: All opioids were effective and well-tolerated. Morphine was the most effective 
in the improvement in some of the Brief Pain Inventory-Short Form items regarding negative 
impact of pain on patients’ daily activities. Prophylaxis of constipation was effective; antiemet-
ics may be considered for nausea prevention.
Keywords: adverse effects, analgesia, opioid analgesics, treatment
Introduction
In 1986, World Health Organization (WHO) experts developed the principles of pain 
treatment in cancer patients based on pharmacological (3-step analgesic ladder) and 
non-pharmacological management, which comprises oncological palliative treatment, 
mainly radiotherapy, intervention techniques of pain treatment: peripheral and central 
blocks, neurolytic blocks, termolesion, kriolesion and neurosurgical procedures.1 
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Pharmacotherapy involves using non-opioid analgesics, 
opioids and co-analgesics (analgesic adjuvants). The most 
frequently recommended route of analgesics administration 
is the oral route, which is usually effective and convenient for 
the patients.2,3 In the recent years, thanks to the availability 
of opioids administered transdermally, the transdermal route 
is the one which is recognized as equally convenient or 
even more convenient than oral route and at the same time 
recommended in those patients who cannot receive drugs by 
oral route. In pain syndromes that are difficult to treat, the 
administration of analgesics and adjuvant analgesics intra-
venously and intrathecally may occasionally produce good 
effects.4 According to European Association for Palliative 
Care (EAPC) and European Society for Medican Oncology 
(ESMO) guidelines, morphine and oxycodone administered 
orally are first-line opioids used to treat moderate-to-severe 
pain, while fentanyl and buprenorphine are alternatives used 
in cancer patients with stable pain syndromes, especially 
when oral administration of opioids is not possible.5,6 Few 
studies compared analgesic efficacy and adverse effects of 
morphine, oxycodone (both administered by an oral route), 
fentanyl and buprenorphine (both administered by the 
transdermal route). Corli et al compared all 4 opioids in an 
explanatory analysis conducted in cancer patients, which 
revealed similar efficacy of all opioids studied.7 All 4 opioids 
were then compared in a randomized study, which demon-
strated similar analgesic efficacy and adverse effects profile 
of patients treated with the drugs studied.8 However, patients’ 
quality of life (QoL) was not evaluated in this study.
The aim of the study was to compare analgesic effect of 
morphine and oxycodone administered by oral route, as well 
as fentanyl and buprenorphine administered transdermally 
in cancer patients with severe pain and the comparison of 
adverse effects of the opioids was studied, including their 
effects on the gastrointestinal functions.
Patients and methods
The trial enrolled patients .18 years old who provided writ-
ten informed consent to participate in the clinical trial, were 
treated in the Home Hospice or Palliative Care Outpatient 
Clinic and diagnosed with cancer and experienced severe pain 
(numerical rating scale [NRS] score 6–10), failed to respond to 
step 1 WHO analgesic ladder drugs and/or weak opioids such 
as tramadol, codeine, dihydrocodeine. The enrollment criteria 
included patients who did not present with cognitive disorders 
as assessed by Mini–Mental State Examination (MMSE), with 
expected survival time of at least 40 days, without renal or liver 
dysfunction. The trial did not enroll patients who had previously 
been treated with strong opioids, those with the symptoms of 
respiratory insufficiency, disorders of consciousness, central 
nervous system primary neoplasm or brain metastases, patients 
who could not receive medications by oral/transdermal route, 
those with clinically significant liver dysfunction (bilirubin 
or transaminase level twice exceeding the norm) and/or renal 
dysfunction (creatinine level above the norm or estimated 
glomerular filtration rate [eGFR] ,60) and patients undergo-
ing chemotherapy. The trial enrolled 62 patients, of whom 32 
were women and 30 men. The group of patients with predomi-
nantly neuropathic pain comprised 30 patients (15 women and 
15 men), while the group with predominantly nociceptive pain 
included 32 patients (18 women and 14 men). The number of 
patients in particular groups is shown in Figure 1.
Table 1 presents basic demographic data and comparison 
of patients’ age in particular patient groups.
Different locations of the primary tumor focus were diag-
nosed in 62 patients participating in the trial. The most com-
mon were located in the gastrointestinal system 15 (24.19%): 
colon 10 (16.13%), stomach 3 (4.84%), esophagus 1 (1.61%) 
and pancreas 1 (1.61%). Lung cancer was diagnosed in 
14 (22.58%), breast in 8 (12.90%) and prostate in 7 (11.29%) 
patients. Tumors of urinary system were found in 6 (9.68%) 
patients, including urinary bladder in 3 (4.84%) and kidney 
in 3 (4.84%) patients; uterus in 4 (6.45%) patients, including 
body 3 (4.84%) and cervix 1 (1.61%) patient. Other loca-
tions (isolated cases): ovary, palatine tonsil, larynx, thyroid 
gland, tongue, skin, carcinoid, primary location unknown 
were diagnosed in 8 (12.90%) patients.
The patients participating in the trial experienced vari-
ous types of pain: visceral, bone, neuropathic and superfi-
cial somatic pain. In the group of 17 patients treated with 
buprenorphine, 1 type of pain was found in 3 patients, 2 or 
more types of pain in 14 patients; in the group of 16 patients 
treated with oxycodone, 1 type of pain was found in 4 patients, 
2 or more types of pain in 12 patients; in the group of 
Figure 1 The number of patients in particular patient groups.
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15 patients treated with fentanyl, 1 type of pain was found 
in 6 patients, 2 or more types of pain in 9 patients; in the 
group of 14 patients treated with morphine, 1 type of pain was 
found in 4 patients, 2 or more types of pain in 10 patients. The 
incidence of occurrence of particular types of pain is shown 
in Table 2.
Methods
The trial protocol and the informed consent form were 
approved by the Bioethical Committee at the University 
of Warmia and Mazury in Olsztyn by 257/13 resolu-
tion of June 10, 2013, No 257/2013. The trial was con-
ducted from September 2013 to December 2015, in the 
following centers:
1. St Lazarus Non-public Palliative Care Centre in 
Biskupiec.
2. MEL–MED Non-public Health Care Centre, Home 
Hospice in Kościan.
3. Puls–Med Non-public Health Care Centre, Palliative 
Outpatient Clinic, Home Hospice in Rybnik.
4. Fr Eugeniusz Dutkiewicz Hospice in Gdańsk.
5. Non-public Palliative Health Care Centre in Kalisz.
All patients meeting the trial enrollment criteria were 
randomized to one of the 4 groups of patients treated with 
buprenorphine, oxycodone, fentanyl or morphine, respec-
tively. In all patient groups, the rescue opioid used for the 
treatment of breakthrough pain episodes was immediate-
release morphine administered by an oral route, titrated to 
satisfactory analgesic effect. The duration of the trial was 
28 days. The patients receiving each opioid were further 
divided into 2 subgroups: patients with predominant nocicep-
tive pain component (bone and/or visceral), and those with 
predominant neuropathic pain component.
The patients could take adjuvant analgesics in bone 
pain and neuropathic pain. To prevent constipation, all 
patients received lactulose in doses of 10 mL administered 
twice daily; no antiemetics were used as prophylaxis. The 
initial doses of the opioids studied were increased to obtain 
effective analgesia (NRS pain intensity #4) and accept-
able severity of adverse effects according to the following 
regimen:
1. Controlled-release morphine administered orally every 
12 h: 2×10, 2×20, 2×30, 2×40, 2×60, 2×90, 2×120, 2×150, 
2×180, 2×200 mg.
2. Controlled-release oxycodone administered orally every 
12 h: 2×5, 2×10, 2×15, 2×20, 2×30, 2×45, 2×60, 2×80, 
2×100, 2×120 mg.
3. Fentanyl administered by transdermal route every 
48–72 h: 25, 37.5, 50, 75, 100, 125, and 150 µg/h.
4. Transdermal buprenorphine administered every 60–84 h: 
35, 52.5, 70, 105, 140, 175, and 210 µg/h.
In this trial, the following research tools were used: 
MMSE to assess cognitive functions,9 Brief Pain Inventory-
Short Form (BPI-SF) to assess pain intensity and its effect 
on patients’ daily activities,10 Edmonton Symptom Assess-
ment System (ESAS) to assess pain, adverse effects and the 
QoL,11 European Organization for Research and Treatment of 
Cancer QoL Questionnaire Core-15-Palliative Care (EORTC 
QLQ-C15-PAL) in order to assess QoL,12 the Bowel Function 
Table 1 Basic demographic data of the patients participating in 
the trial
Patient 
group
Age 
(years)
ANOVA Sex
Buprenorphine 
therapy, n=17
70.0±13.4 F (909.3)=1.858
P=0.147
Men, n=10
58.82%
Women, n=7
41.18%
Oxycodone 
therapy, n=16
72.3±13.2 Men, n=7
43.75%
Women, n=9
56.25%
Fentanyl 
therapy, n=15
70.7±10.9 Men, n=6
40%
Women, n=9
60%
Morphine 
therapy, n=14
62.0±13.4 Men, n=6
42.86%
Women, n=8
57.14%
Patients with 
neuropathic 
pain, n=30
71.0±12.6 F (236.1)=1.398
P=0.242
Men, n=15
50%
Women, n=15
50%
Patients with 
nociceptive 
pain, n=32
67.1±13.4 Men, n=14
43.75%
Women, n=18
56.25%
Total number, 
n=62
69.0±13.0 Men, n=29
46.77%
Women, n=33
53.23%
Notes: age data presented as mean ± standard deviation. F: Fisher test. chi-square 
test; χ2=1.431; df=3; P=0.703.
Abbreviation: anOVa, analysis of variance.
Table 2 The incidence of occurrence of particular types of pain 
(number of patients)
Type of pain Opioid treatment
Buprenorphine Oxycodone Fentanyl Morphine
Visceral 11 10 8 11
Bone 11 10 8 8
neuropathic 7 8 7 8
Superficial 
somatic
5 2 1 0
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Index (BFI) to assess bowel movements,13,14 Hospital  Anxiety 
and Depression Scale (HADS) to assess the emotional 
state15,16 and the Karnofsky scale to assess patients’ perfor-
mance status (PS).17,18
On day 1 of the trial, patients’ cognitive functions were 
assessed using MMSE, and on day 1 and day 28 of the trial, 
patients’ emotional state was assessed by means of HADS. 
On days 1, 7, 14, 21 and 28 of the trial, the QoL was assessed 
by means of EORTC QLQ-C15-PAL, patients’ PS by means 
of the Karnofsky scale, and bowel movements by means of 
BFI. On days 1, 3, 6, 9, 13, 16, 19, 22, 25 and 28 of the trial, 
the patients completed BPI-SF and ESAS.
statistical methods
Statistica data analysis software system, version 12; Stat-
Soft, Inc. 2014 (TIBCO Software Inc., Palo Alto, CA, 
USA) was used for statistical analysis. The results were 
presented as arithmetic mean and standard deviation values, 
minimum and maximum values. In order to compare the 
age of the patients assigned to particular groups, analysis 
of variance (ANOVA), and to compare sex of patients, 
the chi-square test was used. As the data have normal 
distribution confirmed by the Shapiro–Wilk test, and a 
condition of homogeneity of variance was confirmed by 
the Levene test, a 2-factor ANOVA with repeated mea-
surements was used to analyze scores of BPI-SF, ESAS 
and BFI. There were 2 major effects studied: the effect 
of the type of treatment (buprenorphine, oxycodone, fen-
tanyl and morphine), the effect of time of treatment and 
the interactions of the type and duration of therapy. The 
threshold of P,0.05 was adopted as significant.
Results
Over the period of 28 months, in 5 centers altogether, 
62 patients were enrolled in the trial, of whom 53 patients 
managed to complete the treatment. No signs of dementia 
were found in the patients studied: MMSE score was within 
the norm and averaged 28.68 in all patients, 28.72 in the 
group of patients with neuropathic pain and 28.64 in the 
group of patients with nociceptive pain. In this article, we 
report results of pain treatment according to BPI-SF and 
adverse effects according to ESAS of opioids studied.
A separate report of QoL results based on a full analysis 
of ESAS, EORTC QLQ-C15-PAL, HADS and Karnofsky 
will be presented elsewhere.
analgesic effects
According to the trial protocol, the intensity of pain was 
assessed in all patients at baseline and on chosen days of the 
therapy with the opioids studied, using BPI-SF, ESAS and 
EORTC QLQ-C15-PAL. Beneficial effects of the analgesic 
treatment were obtained for all the 4 opioids studied in all 
patients, in those with predominant neuropathic pain and in 
patients with predominant nociceptive pain. The greatest 
reduction in the initial intensity of pain was observed during 
the first 14 days of the trial.
Brief Pain inventory-short Form
Pain intensity
The intensity of pain according to BPI-SF: pain at its worst, 
pain at its least, pain on the average and pain right now 
experienced at the assessment is presented in Table 3. There 
was a significant reduction in the initial pain intensity in all 
pain intensity items.
The results of the 2-factor ANOVA, where the dependent 
variables were pain BPI-SF intensity scales, and the inde-
pendent variables were the type of treatment (buprenorphine, 
oxycodone, fentanyl, morphine) and the time of the therapy 
(days 1, 7, 14, 21 and 28 of the treatment) are shown in 
Table 4.
Table 3 Brief Pain inventory-short Form (BPi-sF) descriptive statistics, items 3–6
BPI-SF items Day 1 Day 3 Day 6 Day 9 Day 13 Day 16 Day 19 Day 22 Day 25 Day 28
Pain at its worst (3) 7.81±0.94
6–10
6.32±1.61
2–10
5.18±1.90
0–8
4.64±2.00
0–9
4.34±1.77
1–9
3.63±1.46
1–8
3.72±1.99
1–10
3.13±1.56
1–9
2.94±1.43
1–9
2.62±1.21
1–6
Pain at its least (4) 5.34±1.80
0–7
4.10±2.01
0–7
3.27±1.91
0–6
2.64±1.82
0–7
2.29±1.56
0–6
1.67±1.39
0–5
1.55±1.46
0–6
1.13±1.35
0–5
0.96±1.04
0–4
0.70±0.90
0–3
Pain on the average (5) 6.77±1.03
3–9
5.27±1.68
1–8
4.32±1.98
0–8
3.49±1.89
0–7
3.13±1.82
0–9
2.65±1.39
0–7
2.57±1.85
0–8
2.08±1.41
0–7
1.87±1.27
0–7
1.57±0.91
0–4
Pain right now (6) 6.69±1.22
1–9
5.06±1.84
0–8
4.08±2.03
0–8
3.44±2.12
0–9
3.04±1.87
0–9
2.54±1.49
0–7
2.40±1.95
0–10
1.92±1.70
0–9
1.85±1.34
0–7
1.57±1.07
0–4
Notes: Mean values, standard deviations, minimum and maximum values are given. The scores are in 11-point scale (range 0–10), with a lower score corresponding to a 
smaller intensity of pain.
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In all items of the BPI-SF (pain at its worst, pain at its 
least, pain on the average, pain right now) pain intensity 
decreased significantly in the course of the treatment with no 
differences between all 4 opioids. A highly significant time 
effect and interactions of treatment time and type of opioid 
therapy were noted in all items of pain intensity.
The effect of pain on chosen dimensions of patients’ 
lives
The effect of pain on particular dimensions of life: general 
activity, mood, the ability to walk, normal work (at home 
and outside the home), relations with other people, sleep and 
enjoyment of life, as assessed by means of BPI-SF question-
naire, are presented in Table 5.
Table 6 presents the results of the 2-factor ANOVA, 
where the dependent variables are the effects of pain on 
particular dimensions of patients’ life in BPI-SF, and inde-
pendent variables the kind of therapy (buprenorphine, oxy-
codone, fentanyl and morphine) and the time of treatment 
(days 7, 14, 21 and 28 of therapy).
The effect of pain on general activity
Considering the effect of pain on general activity of patients, 
a slightly better but insignificant effect of morphine, when 
compared with other opioids, is of note (P=0.067). The effect 
of pain on general activity of patients in relation to the dura-
tion of therapy was significant (P,0.001).
The effect of pain on mood
The reduction in negative effect of pain on patients’ mood 
was associated with time of the treatment (P,0.001) with no 
difference between opioids studied. The effect was observed 
mainly during the first 14 days of the trial.
The effect of pain on the ability to walk
Considering the effect of pain on patients’ ability to walk, sig-
nificant effects of the type and time of treatment (P,0.001) 
were observed. Out of the opioids studied, the best effects 
were obtained during morphine therapy (P=0.021).
The effect of pain on normal work
In terms of the effect of pain on normal work, significant 
differences occurred with regard to all the 3 effects studied. 
Table 4 The results of the Brief Pain inventory-short Form two-
factor analysis of variance
Item Main effects F P-value
Pain at its worst (3) 1
2
3
1.326 (3)
108.950 (9)
2.559 (27)
0.276
,0.001
,0.001
Pain at its least (4) 1
2
3
1.140 (3)
102.076 (9)
1.575 (27)
0.342
,0.001
0.035
Pain on the average (5) 1
2
3
0.687 (3)
130.044 (9)
2.733 (27)
0.564
,0.001
,0.001
Pain right now (6) 1
2
3
0.944 (3)
99.985 (9)
2.326 (27)
0.427
,0.001
,0.001
Notes: F: Fisher test, the degrees of freedom are given in parentheses. P, significance 
level. Main effects: 1, the drug effect; 2, time effect; 3, interactions of 1 and 2. item: 
the numbers in parentheses indicate item number in the questionnaire. Significant 
values are marked in bold.
Table 5 Descriptive statistics for items 9a–9g Brief Pain inventory-short Form (BPi-sF) concerning the effect of pain on particular 
dimensions of patients’ life
BPI-SF 
items
Day 1 Day 3 Day 6 Day 9 Day 13 Day 16 Day 19 Day 22 Day 25 Day 28
9a 6.47±1.77
2–10
5.69±1.90
2–10
4.95±2.00
0–10
4.43±1.86
0–8
3.89±1.98
0–9
3.46±1.86
0–8
3.60±2.097
0–9
3.26±2.02
1–9
3.13±1.98
0–9
2.87±1.86
0–9
9B 5.37±2.28 
0–10
4.76±2.21
0–8
4.31±2.29
0–8
3.79±2.12
0–8
3.59±2.27
0–10
3.15±1.91
0–8
3.32±2.06
0–9
3.04±1.81
0–8
2.89±1.95
0–8
2.72±2.02
0–9
9c 5.85±2.60
0–10
5.31±2.71
0–10
4.77±2.79
0–10
4.36±2.66
0–10
4.20±2.88
0–10
3.74±2.80
0–10
3.70±2.91
0–10
3.36±2.82
0–10
3.21±2.87
0–10
3.13±3.01
0–10
9D 6.42±2.41
1–10
5.61±2.56
0–10
5.13±2.65
0–10
4.66±2.54
0–10
4.41±2.67
0–10
4.06±2.72
0–10
3.98±2.59
0–10
3.51±2.55
0–10
3.43±2.71
0–10
3.26±2.86
0–10
9e 4.95±2.00
0–10
4.37±1.88
0–8
3.90±2.01
0–9
3.36±1.64
0–8
3.39±1.96
0–10
2.70±1.55
0–7
2.85±1.93
0–9
2.53±1.81
0–9
2.15±1.68
0–8
1.92±1.52
0–5
9F 4.13±2.41
0–9
3.65±2.31
0–10
3.29±2.08
0–8
2.95±2.11
0–9
3.00±2.16
0–9
2.48±1.76
0–7
2.47±2.01
0–10
2.23±2.06
0–10
2.04±1.69
0–6
2.00±1.69
0–6
9g 5.34±2.22
0–10
4.65±2.21
0–10
4.13±2.26
0–9
3.74±2.10
0–9
3.55±2.04
0–8
3.04±1.80
0–7
3.06±1.91
0–8
2.77±1.96
0–9
2.57±1.85
0–9
2.32±1.76
0–8
Notes: 9a, general activity; 9B, mood; 9c, ability to walk; 9D, normal work (at home and outside the home); 9e, relations with other people; 9F, sleep; 9g, enjoyment of 
life. There are mean values, followed by standard deviations, minimum and maximum values. The scores are given in 11-point scale (range 0–10). a lower score denotes a 
smaller negative effect of pain on particular dimensions of patients’ life.
 
D
ru
g 
D
es
ig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
95
.1
74
.4
5.
14
5 
on
 2
8-
M
ar
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2017:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2414
nosek et al
The smallest negative effect of pain on normal work was 
observed during morphine therapy (P=0.017). The effect of 
pain on work in relation to time of treatment was significant 
(P,0.001). Interactions of the type and time of treatment 
with regard to the effect of pain on performing normal work 
by patients were significant (P=0.049).
The effect of pain on relations with other people, 
sleep and enjoyment life
Analyzing a negative effect of pain on relations with other 
people, significant effects with regard to the time of treatment 
as well as interactions of type and time of treatment were 
observed (P,0.001). In terms of the effect of pain on sleep, 
a significant effect occurred (P,0.001) with regard to time 
of treatment. Analyzing a negative effect of pain on enjoy-
ment of life, significant effects of time of treatment as well 
as interaction of type and time of treatment were observed 
(P,0.001).
Doses of opioids
The doses of opioids were adjusted depending on the analge-
sic effect and adverse effects; for the majority of the patients, 
the initial dose had to be increased. The range of the doses 
for the opioids studied was 35–140 µg/h for buprenorphine, 
25–100 µg/h for fentanyl, 10–60 mg/day for oxycodone 
and 20–80 mg/day for morphine. Average daily doses of 
morphine and oxycodone, average hourly doses of fentanyl 
and buprenorphine with percentile increases compared with 
initial doses in all patients are shown in Table 7.
Average use of immediate-release morphine adminis-
tered by oral route in the treatment of breakthrough pain, 
during 28 days of treatment in all patients, in the group of 
patients with neuropathic pain and nociceptive pain is shown 
in Table 8.
non-opioid analgesics, step 2 opioids, adjuvant 
analgesics
Prior to the trial, the patients used the following drugs: 
57 patients received tramadol, 52 paracetamol, 30 ketoprofen, 
10 metamizol, 3 patients received diclofenac and 3 received 
dexamethasone, meloxicam and ibuprofen were taken by 
2 patients each. On day 28 of the trial, 16 patients took par-
acetamol, 12 dexamethasone, 4 ketoprofen; gabapentin, car-
bamazepine and amitriptyline were taken by 2 patients each, 
ibuprofen and dexketoprofen were taken by 1 patient each.
Table 6 The results of Brief Pain inventory-short Form two–
factor analysis of variance for items 9a–9g
Pain interference with Main effects F P-value
general activity (9a) 1
2
3
2.543 (3)
51.092 (9)
1.125 (27)
0.067
,0.001
0.305
Mood (9B) 1
2
3
1.266 (3)
28.290 (9)
1.408 (27)
0.296
,0.001
0.086
The ability to walk (9c) 1
2
3
3.547 (3)
31.016 (9)
1.090 (27)
0.021
,0.001
0.347
normal work (9D) 1
2
3
3.734 (3)
32.131 (9)
1.512 (27)
0.017
,0.001
0.049
relations with other people (9e) 1
2
3
2.074 (3)
44.375 (9)
2.141 (27)
0.116
,0.001
,0.001
sleep (9F) 1
2
3
0.419 (3)
20.974 (9)
0.705 (27)
0.740
,0.001
0.864
enjoyment of life (9g) 1
2
3
0.732 (3)
48.190 (9)
2.365 (27)
0.538
,0.001
,0.001
Notes: F: Fisher test, degrees of freedom are given in parentheses. P, significance 
level. Main effects: 1, the effect of the drug; 2, the effect of time; 3, interactions of 1 and 
2. 9A–9G, item numbers of the questionnaire. Significant values are marked in bold.
Table 7 hourly doses of buprenorphine and fentanyl and mean daily doses of oxycodone and morphine and percentage increase of 
the average daily doses of opioids studied compared to the initial daily doses, in all patients
Time Opioid doses Buprenorphine Oxycodone Fentanyl Morphine
Day 1 initial dose 35 µg/h 10 mg/day 25 µg/h 20 mg/day
Day 7 range
Mean ± sD
Dose increase
35–52 µg/h
43.23±10.90 µg/h
23.51%
10–40 mg
19.37±7.72 mg
93.70%
25–50 µg/h
30.12±11.44 µg/h
20.48%
20–40 mg
32.46±12.22 mg
63.20%
Day 14 range
Mean ± sD
Dose increase
35–70 µg/h
54.83±11.20 µg/h
56.65%
10–40 mg
22.58±7.932 mg
125.80%
25–50 µg/h
35.41±12.87 µg/h
41.64%
20–60 mg
40.00±14.77 mg
100.00%
Day 21 range
Mean ± sD
Dose increase
35–105 µg/h
60.66±17.33 µg/h
73.31%
20–40 mg
27.70±9.81 mg
177.00%
25–75 µg/h
42.50±20.58 µg/h
70.00%
20–80 mg
51.66±15.86 mg
158.30%
Day 28 range
Mean ± sD
Dose increase
35–140 µg/h
63.00±24.57 µg/h
80.00%
20–60 mg
31.64±13.70 mg
216.40%
25–100 µg/h
45.00±25.82 µg/h
80.00%
20–80 mg
56.66±11.54 mg
183.30%
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adverse effects
Out of 62 patients, 9 did not complete the trial: 5 patients died, 
3 patients resigned from participation in the trial: 2 because of 
adverse events (dizziness, nausea and vomiting, skin lesions), 
1 due to lack of consent to complete the research tools, 1 was 
referred to hospital because of deteriorated general health 
status (Figure 2).
In the group of 30 patients with neuropathic pain, 
26 (86.67%) patients completed the treatment lasting 
28 days; 3 (10%) patients died and 1 (3.33%) patient receiv-
ing morphine decided to discontinue the therapy on day 7 
of the trial due to its adverse effects: dizziness, nausea and 
vomiting. In the group of 32 patients with nociceptive pain, 
27 (84.37%) patients completed the trial; 2 (6.25%) patients 
died, 2 (6.25%) patients resigned from participating in the 
trial (1 patient treated with fentanyl due to lack of consent to 
complete the research tools, 1 patient treated with buprenor-
phine on day 12 of the trial due to adverse effects: skin 
lesions, malaise, nausea and vomiting), 1 (3.13%) patient 
treated with fentanyl on day 12 of the trial was referred to 
hospital due to disorders of consciousness. ESAS and BFI 
were used to assess adverse events.
edmonton symptom assessment system
According to ESAS, there were no changes in constipation, 
vomiting and dyspnea.
Drowsiness
The severity of drowsiness has changed in relation to 
treatment time (P=0.009). An increase in the severity of 
Table 8 The use of immediate-release morphine administered by oral route in milligrams, in the treatment of breakthrough pain in 
all patients during 28 days, in the group of patients with neuropathic pain and nociceptive pain; mean values and standard deviations 
are given
Patient group Buprenorphine Oxycodone Fentanyl Morphine
all patients (n=62) 457.65±479.47 338.13±273.94 390.67±377.48 260.00±327.04
Patients with neuropathic pain (n=30) 657.50±552.13 361.25±287.7 557.14±360.22 280.00±409.06
Patients with nociceptive pain (n=32) 280.00±342.93 315.00±277.49 280.00±361.48 240.00±251.93
Figure 2 Flowchart of the study.
 
D
ru
g 
D
es
ig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
95
.1
74
.4
5.
14
5 
on
 2
8-
M
ar
-2
02
0
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2017:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2416
nosek et al
drowsiness was found during the first 9 days of therapy and 
a gradual decrease in the symptom severity was observed on 
the following days of the trial.
nausea and appetite
The severity of nausea changed in relation to treatment 
time (P,0.001). An increase in the severity of nausea was 
found during the first 9 days of treatment and a gradual 
symptom resolution on the following days of the trial. Loss 
of appetite changed in relation to time of the treatment 
(P,0.001). A gradual improvement in appetite was found 
during therapy.
Depression, anxiety, tiredness and well-being
The level of depression changed in relation to treatment time 
(P,0.001). A gradual reduction in the severity of depression 
was found on the following days of the trial. The effect of 
treatment time was observed with regard to anxiety, fatigue 
and well-being (P,0.001); for the well-being, there was 
also a significant effect of interaction of type of treatment 
and treatment time (P=0.001). There was a gradual reduc-
tion in the anxiety level and severity of tiredness as well as 
improvement of well-being during the therapy.
The Bowel Function index
The assessment of severity of constipation was made using 
the BFI. In terms of constipation assessed by BFI, no sig-
nificant changes in the symptom severity were found during 
the treatment with respect to all the ANOVA effects studied. 
Moreover, the mean scores of BFI in all measurements for 
all 4 opioids were within normal range.
Discussion
A randomized, multi-center, parallel-group clinical trial 
aimed to compare the analgesic effect and adverse effects of 
patients remaining under care of the Home Hospice or Pallia-
tive Outpatient Clinic who were diagnosed with cancer and 
who, due to severe pain (6–10 by NRS), required the use of 
opioid analgesics. For the purpose of pain treatment, one of 
the 4 opioids was used: morphine or oxycodone in the form 
of controlled-release tablets administered orally or fentanyl 
or buprenorphine administered transdermally.
analgesic effects
Buprenorphine, oxycodone, fentanyl and morphine both in 
patients with neuropathic as well as nociceptive pain were 
effective analgesics, which was expressed by the reduction 
in the mean value of the baseline severity of pain in NRS 
(statistically significant differences) with respect to pain at 
its worst, pain at its least, pain on the average and pain right 
now assessed by BPI-SF. Similar effects of statistically 
significant reduction in the initial severity of pain were also 
seen in ESAS and EORTC QLQ-C15-PAL pain assessment 
scales (data not shown).
No statistically significant differences were proved in 
terms of reduction in pain between the groups of patients 
with neuropathic and nociceptive pain. This is probably 
due to the fact that most patients experienced pain that was 
mixed in character, with nociceptive and neuropathic pain 
component (71% patients experienced at least 2 types of 
pain), and they qualified for the type of pain subgroup on 
the basis of the prevailing type of pain. In the conducted 
trial, patients with predominantly neuropathic pain required 
higher doses of morphine in the treatment of breakthrough 
pain in comparison with patients with nociceptive pain. This 
applied to all the opioids studied. Additionally, the require-
ment for morphine to treat breakthrough pain during the 
treatment with opioids administered transdermally (fentanyl 
and buprenorphine) was twice as high as during the treatment 
with opioids administered orally, which indirectly suggests 
the higher efficacy of morphine and oxycodone in the treat-
ment of neuropathic pain. More patients with neuropathic 
pain required the use of adjuvant analgesics (dexamethasone, 
antiepileptic and/or antidepressant) and paracetamol, which 
confirmed that pain with the neuropathic component was 
more difficult to treat.
No statistically significant differences were proved in 
the severity of pain in patients treated with slow-release oral 
morphine and oxycodone in comparison with those treated 
with fentanyl and buprenorphine used transdermally.19–21 
During the trial, no statistically significant differences were 
found in terms of degree and speed of onset of analgesic 
effect for particular opioids, although in case of using 
buprenorphine, there was a tendency to achieve complete 
analgesia later, which resulted from its pharmacokinetic and 
pharmacodynamic properties.22
Regarding the time which elapses from the beginning of 
the therapy with the studied opioids to the moment effective 
analgesia is obtained, it was seen that all 4 drugs caused a 
significant reduction in the initial severity of pain measured 
by means of NRS, with the effect observed mainly during the 
first 14 days of the therapy, which correlated with substantial 
improvement of the overall QoL (data not shown) during this 
period of therapy. The analgesic effect of the studied opioids 
in the subsequent 14 days of the therapy remained on a more 
stable level. Although the first analgesic effects of opioids 
can be seen shortly after the drug is administered (minutes, 
hours), a period of 14 days may be regarded as the time which 
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is necessary for the adequate assessment of the full opioid 
analgesic effect, both in the clinical trials and in everyday 
practice of pain treatment in cancer patients.
Limited number of clinical trials compared all the 4 opi-
oids studied. In the open randomized clinical trial conducted 
on 108 cancer patients, who did not respond to weak opioids 
therapy, slow-release morphine (initial dose of 60 mg/day) 
and methadone (initial dose 15 mg/day) were administered 
by oral route and fentanyl (initial dose 25 µg/h) was admin-
istered transdermally for 28 days. A comparable analgesic 
efficacy as well adverse effects and patients’ QoL were 
observed during the treatment with the opioids studied.23 In a 
study conducted in Italy, analgesia, adverse effects and QoL 
during treatment with morphine and oxycodone adminis-
tered orally with buprenorphine and fentanyl administered 
transdermally were compared.7 However, the trial opioids 
were compared indirectly, by studying observations in the 
course of the treatment with particular drugs, without random-
ization, with patients receiving a given opioid at the doctor’s 
discretion (the trial was observational in character). A newer 
and large Italian clinical study comprising over 520 patients 
showed similar effectiveness and tolerance regarding adverse 
effects of the 4 opioids studied.8 The results of all these 
studies are in line with the scores obtained in our study.
Over the course of treatment, an increase in average daily 
opioid doses was seen, which became clear in the light of the 
fact that the treatment was commenced with low doses, which 
were gradually increased to obtain appropriate analgesia 
and acceptable adverse effects (titration). Of note, a similar 
percentile increase in doses occurred for buprenorphine and 
fentanyl as well as for oxycodone and morphine. A signifi-
cantly higher percentile increase in the doses of oxycodone 
and morphine resulted from lower initial equivalent doses 
in comparison with buprenorphine and fentanyl. It should 
be noted that there were similar proportions of the average 
doses of buprenorphine and fentanyl, which indicates an 
accurate choice and probably equivalent analgesic effect of 
35 µg dose of buprenorphine and 25 µg dose of fentanyl. 
In case of oxycodone and morphine administered orally, the 
equivalent doses ratio within the proportion of 1:1.5 and 1:2, 
although a smaller negative effect of pain on walking ability 
and normal work (BPI-SF) as well as a greater improvement 
in the physical function of patients (EORTC QLQ-C15-PAL, 
data not shown) were seen during morphine therapy.
adverse effects
The adverse effects seen in the patients during the trial were, 
as a rule, characterized by small severity, but for 3 patients, 
they were the reason to discontinue the trial. When the opioid 
doses are adjusted correctly to the severity of pain (titration), 
serious adverse effects occur extremely rarely. Most adverse 
effects are usually transient, except for opioid-induced bowel 
dysfunction, particularly constipation, which occurs through-
out the course of the opioid therapy.
The most common adverse effects occurring in the 
patients undergoing treatment included nausea and drowsi-
ness. At the beginning of the trial, nausea was observed in 
15 patients: in 11 patients, its severity was small; in 4 of them, 
nausea was severe. The severity of nausea increased over 
the first 7 days of treatment; during the following 14 days, 
it remained on much the same level; and in the last week of 
the trial, it decreased (the effect of treatment time in EORTC 
QLQ-C15-PAL and ESAS). 
No significant differences were found between the 
4 opioids in the severity of nausea, but there was a tendency 
for a greater severity of nausea in patients treated with mor-
phine. According to the trial protocol, patients did not receive 
antiemetics when a particular opioid was started. Currently, 
EAPC does not recommend prophylactic antiemetic manage-
ment when the opioid therapy is commenced;5 moreover, 
experts of the Multinational Association of Supportive Care 
in Cancer and ESMO were unable to render any recom-
mendations on the management of opioid-induced nausea 
and vomiting.24 However, antiemetics may be recommended 
at the beginning of the opioid therapy in patients with risk 
factors. In order to resolve controversies about the mandatory 
introduction of antiemetics when the opioid therapy is com-
menced, further controlled clinical trials are required.
In case of vomiting and constipation, no significant differ-
ences were found. Out of the patients participating in the 
trial, only 8 patients showed no symptoms connected with 
constipation, and in all the remaining patients, the symptoms 
differed in severity. Considering BFI scores on day 28, 15 
(24%) patients suffered from constipation (mean BFI score 
over 3), while for 11 (17.74%) patients, BFI scores on day 28 
were higher, when compared with those from the beginning 
of the trial. However, no mean values .3 were found in the 
assessment of the severity of constipation conducted in all 
patients, either for any of the particular 3 items or mean BFI 
scores. This proves the efficacy of constipation prophylaxis, 
which is further confirmed by the fact that the severity of 
constipation did not increase during the trial, according to 
BFI, ESAS and EORTC QLQ-C15-PAL. According to the 
guidelines of International Expert Panel, all patients received, 
as prophylaxis, lactulose at the dose of 10 mL twice daily 
and an adequate fluid provision.14 One of the factors which 
could have contributed to the effective prophylaxis was 
a relatively good general health status of the patients 
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(mean Karnofsky value over 60, data not shown), thanks 
to which the patients could perform physical activity as 
recommended, at the level that was adjusted to individual 
possibilities of particular patients.
Drowsiness, in much the same way as nausea, increased 
gradually over the first 14 days of the trial, and then gradu-
ally decreased (ESAS time effect). Patients .70 years of 
age are more at risk of developing disorders of conscious-
ness associated with the use of opioids, which results from 
the occurrence of comorbidities, particularly kidney and 
liver dysfunction, which may exacerbate the adverse effects 
caused by opioids, for example, due to accumulation of mor-
phine metabolites. Patients with impaired renal or hepatic 
function were not enrolled onto the trial. Patients’ average age 
was the lowest in the group of patients receiving morphine 
(62 years of age), and the highest in the group of patients 
treated with oxycodone (.72 years of age). The results of 
the present study concerning the severity of drowsiness are 
congruent with the state-of-the-art knowledge about the 
adverse effects of opioids.25
With respect to loss of appetite assessed by ESAS and 
EORTC QLQ-C15-PAL (data not shown), the effect of time 
was observed. The improvement in appetite occurred mainly 
in the first 14 days of treatment, which may be associated with 
the analgesic effect that also showed a similar tendency. This 
could beneficially influence the patients’ QoL, which was 
confirmed by the improvement in overall QoL, also observed 
during the first 14 days of treatment. The trial did not include 
the assessment of dry mouth (xerostomia), which could also 
influence the level of appetite. No differences were found in 
dyspnea, although 14 (22.58%) patients participating were 
diagnosed with lung cancer, because the severity of dyspnea 
in the trial patients was small.
strengths and limitations of the study
Strengths of the trial include the comparison of 4 opioids 
in terms of analgesia, adverse effects and QoL, random-
ization, a multicenter design, a long monitoring period 
and use of several methods for assessment of pain, other 
symptoms and QoL. The compatibility of results yielded 
by various research tools indicates their accuracy, reli-
ability, sensitivity to change, and usefulness in the clinical 
practice and for monitoring of symptomatic treatment of 
cancer patients.
A serious limitation to the trial is the small number of 
patients enrolled due to substantial difficulties with patient 
enrollment connected with, among others, the pre-condition 
of not having been treated with strong opioids, the use of 
which is now common practice in cancer patients with 
severe pain. Other limitations include no blind trial and pla-
cebo use, which may, however, be explained by significant 
inconvenience for the patients connected with the necessity 
of taking a drug or placebo both orally and transdermally as 
well as ethical doubts associated with administering placebo 
to cancer patients with severe pain.
Conclusion
In the treatment of severe pain in cancer patients, buprenor-
phine, oxycodone, fentanyl and morphine show similar anal-
gesic efficacy, with the full analgesic effect being achieved 
gradually, mainly during the first 14 days of treatment. 
In comparison with buprenorphine, oxycodone and fentanyl, 
during the morphine therapy, a smaller negative effect of 
pain on walking ability and work was observed; there was a 
smaller use of rescue morphine administered in the treatment 
of breakthrough pain. The trial opioids showed a similar 
profile and the severity of adverse effects. The prophylaxis 
of laxatives prevented opioid-induced constipation. At the 
beginning of the opioid therapy, prophylactic use of antiemet-
ics may be considered in order to avoid nausea.
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